SCHEMBL7944671

SCHEMBL7944671

Nc1ncccc1NCc1cccc(NC(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.64
GAA P10253 2/20 0.58
KDM4E B2RXH2 1/20 0.58
AURKA O14965 3/20 0.58
AURKB Q96GD4 3/20 0.58
PARP1 P09874 1/20 0.53
PARP2 Q9UGN5 1/20 0.53
HDAC1 Q13547 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
KDR P35968 1/20 0.49
GRM4 Q14833 1/20 0.48
MEN1 O00255 1/20 0.48
PABPC1 P11940 1/20 0.48
KMT2A Q03164 1/20 0.48
EIF4H Q15056 1/20 0.48
NAMPT P43490 1/20 0.47
ACKR3 P25106 1/20 0.47
CYP11B1 P15538 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7944661 0.88 BACE1 (0.71) BACE1GAAKDM4EAURKAAURKB
SCHEMBL7939887 0.88 BACE1 (0.59) BACE1KDM4EAURKAAURKBNPC1
SCHEMBL7940344 0.87 BACE1 (0.69) BACE1AURKAAURKBHDAC1NPC1
SCHEMBL7942885 0.87 BACE1 (0.61) BACE1GAAAURKAAURKBNPC1
SCHEMBL7942206 0.86 BACE1 (0.66) BACE1GAAKDM4EAURKAAURKB
SCHEMBL7940998 0.85 GAA (0.50) BACE1GAAKDM4EAURKAAURKB
SCHEMBL7942210 0.84 BACE1 (0.62) BACE1AURKAAURKBKDRGRM4
SCHEMBL7933421 0.84 BACE1 (0.62) BACE1AURKAAURKBKDRGRM4
SCHEMBL7940967 0.83 BACE1 (0.57) BACE1GAAKDM4EAURKAAURKB
SCHEMBL7940722 0.83 BACE1 (0.76) BACE1AURKAAURKBHDAC1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885GAA 613/4885KDM4E 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.